Israel Englander Pyxis Oncology, Inc. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 815,331 shares of PYXS stock, worth $3.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

815,331

Previous 3,539,860 76.97%

Holding current value

$3.68 Million

Previous $3.89 Million 54.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.04 - $2.32 $2.83 Million - $6.32 Million	-2,724,529 Reduced 76.97%	815,331 $1.78 Million
Q2 2025 Aug 14, 2025	BUY	$0.88 - $1.35 $928,033 - $1.42 Million	1,054,584 Added 42.43%	3,539,860 $3.89 Million
Q1 2025 May 15, 2025	SELL	$0.98 - $1.76 $485,717 - $872,308	-495,630 Reduced 16.63%	2,485,276 $2.44 Million
Q4 2024 Feb 14, 2025	BUY	$1.54 - $4.77 $1.65 Million - $5.12 Million	1,073,928 Added 56.32%	2,980,906 $4.62 Million
Q3 2024 Nov 14, 2024	BUY	$2.83 - $3.94 $1.61 Million - $2.25 Million	570,070 Added 42.64%	1,906,978 $7 Million

Q2 2024 Aug 14, 2024	BUY	$3.06 - $5.58 $2.31 Million - $4.21 Million	753,899 Added 129.31%	1,336,908 $4.43 Million
Q1 2024 May 15, 2024	BUY	$2.03 - $6.59 $1.16 Million - $3.75 Million	569,737 Added 4292.77%	583,009 $2.48 Million
Q4 2023 Feb 14, 2024	SELL	$1.4 - $2.09 $24,648 - $36,796	-17,606 Reduced 57.02%	13,272 $23,000
Q2 2023 Aug 14, 2023	BUY	$2.46 - $4.07 $75,959 - $125,673	30,878 New	30,878 $79,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $2.0 $66,694 - $117,008	-58,504 Reduced 65.12%	31,334 $42,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $3.03 $99,596 - $160,520	-52,977 Reduced 37.09%	89,838 $177,000

Others Institutions Holding PYXS

# of Institutions

Shares Held

22.6M

Call Options Held

21.5K

Put Options Held

View Full List

About Pyxis Oncology, Inc.

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $158M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

More about PYXS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account